RESEARCH - Effects of anti-TNF therapy on lipid profile in patients with RA

[Guest guest]

Joint Bone Spine. 2008 Jan;75(1):22-4. Epub 2007 Aug 27.

Effects of anti-tumor necrosis factor therapy on lipid profile in

patients with rheumatoid arthritis.

Soubrier M, Jouanel P, Mathieu S, Poujol D, Claus D, Dubost JJ, Ristori JM.

Service de Rhumatologie, Hôpital G. Montpied, Place Henri Dunant, BP

69, 63003 Clermont-Ferrand Cedex 1, France.

OBJECTIVES: Analyse the effects of anti-tumor necrosis factor therapy

on serum levels of lipid in patients with rheumatoid arthritis (RA).

METHODS: Twenty-nine patients (26 females, 3 males) with established

RA undergoing anti-TNF therapy (n=12, adalimumab; n=11, infliximab;

n=6, etanercept) were recruited. Total cholesterol, LDL-cholesterol,

HDL-cholesterol, triglycerides (TG), and apolipoproteins (apo b and

apo a) were assessed at baseline and after 14 weeks of treatment.

RESULTS: The disease activity index score (DAS(28)) was 5.19+/-0.90

and decreased to 3.46+/-0.97 at 16 weeks (p<0.001). There was no

change neither in the levels of TC (5.65+/-0.98mmol/l vs

5.78+/-1.06mmol/l; p=0.43), TG (1.40+/-0.79mmol/l vs

1.45+/-0.67mmol/l; p=0.59), HDL-C (1.92+/-0.49mmol/l vs

1.97+/-0.49mmol/l; p=0.36), apo a1 (1.92+/-0.28g/l vs 1.99+/-0.29g/l;

p=0.06), and LDL-C (3.41+/-0.91mmol/l vs 3.47+/-0.96mmol/l; p=0.66),

nor in apo b (1.126+/-0.302g/l vs 1.13+/-0.28g/l; p=0.89), atherogenic

index (3.13+/-1.05 vs 3.09+/-0.89; p=0.69) or the apo b/apo a1 ratio

(0.58+/-0.25 vs 0.56+/-0.22; p=0.33).

CONCLUSION: The favourable effect of anti-tumor necrosis factor

therapy on cardiovascular morbidity is not related to effects on lipid

metabolism.

PMID: 17888710

http://www.ncbi.nlm.nih.gov/pubmed/17888710

Not an MD